» Articles » PMID: 30756197

Detecting Secular Trends in Clinical Treatment Through Temporal Analysis

Overview
Journal J Med Syst
Date 2019 Feb 14
PMID 30756197
Citations 1
Authors
Affiliations
Soon will be listed here.
Abstract

Medical treatments change over time for multiple reasons, including introduction of new treatments, availability of new scientific evidence, change in institutional guidelines, and market efforts by pharmaceutical and medical device companies. Monitoring and analyzing these secular trends will also inform the evaluation of evidence based practice as well as outcome research. Using a large national clinical dataset from the United States Veterans Health Administration (VHA), we measured the change in prevalence of all diseases, medications, and procedures by year from 2001 to 2014. To assess statistical significance, we used a generalized linear model. Among the large number of changes that were observed, multiple significant changes were related to diabetes mellitus type II (DM2). Prevalence of DM2 in the VHA increased after 2001 but plateaued by 2008; blood sugar testing by glycosylated hemoglobin increased consistently while glucose testing decreased; and the trend of insulin and metformin use was consistent with the trend in DM2 prevalence, while glyburide and rosiglitazone use dropped sharply.

Citing Articles

Including non-concurrent control patients in the analysis of platform trials: is it worth it?.

Lee K, Wason J BMC Med Res Methodol. 2020; 20(1):165.

PMID: 32580702 PMC: 7315495. DOI: 10.1186/s12874-020-01043-6.

References
1.
Friedman C, Kra P, Rzhetsky A . Two biomedical sublanguages: a description based on the theories of Zellig Harris. J Biomed Inform. 2003; 35(4):222-35. DOI: 10.1016/s1532-0464(03)00012-1. View

2.
Pepin J, Valiquette L, Alary M, Villemure P, Pelletier A, Forget K . Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity. CMAJ. 2004; 171(5):466-72. PMC: 514643. DOI: 10.1503/cmaj.1041104. View

3.
Miedema K . Standardization of HbA1c and Optimal Range of Monitoring. Scand J Clin Lab Invest Suppl. 2005; 240:61-72. DOI: 10.1080/00365510500236143. View

4.
Etzioni D, Mack T, Beart Jr R, Kaiser A . Diverticulitis in the United States: 1998-2005: changing patterns of disease and treatment. Ann Surg. 2009; 249(2):210-7. DOI: 10.1097/SLA.0b013e3181952888. View

5.
Loke Y, Kwok C, Singh S . Comparative cardiovascular effects of thiazolidinediones: systematic review and meta-analysis of observational studies. BMJ. 2011; 342:d1309. PMC: 3230110. DOI: 10.1136/bmj.d1309. View